Y-mAbs' naxitamab shows promise in treating high-risk neuroblastoma. Explore its phase 2 success, strong cash runway, and ...

The Cell Shuttle was designed to help academic cell therapy developers by providing an integrated, automated solution.

In the keynote talk, Dr Crystal Mackall from Stanford University presented data from the ongoing Phase I, open-label, single-centre clinical trial of GD2-CAR cells in diffuse midline gliomas (DMG) and ...

Cellares and the University of Wisconsin School of Medicine and Public Health announced a new partnership April 10.

New research shows that GD2 CAR-T cell therapy offers a potential cure for neuroblastoma, with some patients achieving long-term remission for over a decade—marking a major milestone in solid ...

Hu14.18 is a humanised anti-GD2 monoclonal antibody that is being tested in a phase 2 trial as an add-on to standard induction chemotherapy for the treatment of newly diagnosed high-risk ...